Emerging topics in dementia care and services
Abstract Background The National Institute on Aging (NIA), in conjunction with the
Department of Health and Human Services as part of the National Alzheimer's Project Act …
Department of Health and Human Services as part of the National Alzheimer's Project Act …
The major hypotheses of Alzheimer's disease: related nanotechnology-based approaches for its diagnosis and treatment
C Cáceres, B Heusser, A Garnham, E Moczko - Cells, 2023 - mdpi.com
Alzheimer's disease (AD) is a well-known chronic neurodegenerative disorder that leads to
the progressive death of brain cells, resulting in memory loss and the loss of other critical …
the progressive death of brain cells, resulting in memory loss and the loss of other critical …
Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: an instrumental variable meta‐analysis
Introduction Whether the reduction in brain amyloid beta (Aβ) plaque alone may
substantially slow cognitive and functional decline in patients with dementia or mild …
substantially slow cognitive and functional decline in patients with dementia or mild …
Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation
HW Klafki, J Vogelgsang, E Manuilova, C Bauer… - Alzheimer's research & …, 2022 - Springer
Background Measurements of the amyloid-β (Aβ) 42/40 ratio in blood plasma may support
the early diagnosis of Alzheimer's disease and aid in the selection of suitable participants in …
the early diagnosis of Alzheimer's disease and aid in the selection of suitable participants in …
Plasma p‐tau181/Aβ1‐42 ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ1‐42 and future cognitive decline
CJ Fowler, E Stoops, SR Rainey‐Smith… - Alzheimer's & …, 2022 - Wiley Online Library
Abstract Background In Alzheimer's disease (AD), plasma amyloid beta (Aβ) 1‐42 and
phosphorylated tau (p‐tau) predict high amyloid status from Aβ positron emission …
phosphorylated tau (p‐tau) predict high amyloid status from Aβ positron emission …
Acceptable performance of blood biomarker tests of amyloid pathology—recommendations from the Global CEO Initiative on Alzheimer's Disease
SE Schindler, D Galasko, AC Pereira… - Nature Reviews …, 2024 - nature.com
Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become
clinically available in some countries, which has greatly increased the need for biomarker …
clinically available in some countries, which has greatly increased the need for biomarker …
The structural combination of SIL and MODAG scaffolds fails to enhance binding to α-synuclein but reveals promising affinity to amyloid β
A Di Nanni, RS Saw, GD Bowden, NSR Bidesi… - Molecules, 2023 - mdpi.com
A technique to image α-synuclein (αSYN) fibrils in vivo is an unmet scientific and clinical
need that would represent a transformative tool in the understanding, diagnosis, and …
need that would represent a transformative tool in the understanding, diagnosis, and …
Improvement of electroacupuncture on APP/PS1 transgenic mice in behavioral probably due to reducing deposition of Aβ in hippocampus
RQ Sun, ZD Wang, J Zhao, S Wang… - The Anatomical …, 2021 - Wiley Online Library
Alzheimer's disease (AD) is a fatal neurodegenerative disease for which currently no cure is
available. Electroacupuncture (EA) has been widely used in China as an alternative …
available. Electroacupuncture (EA) has been widely used in China as an alternative …
Current status of PET tracers for the early diagnosis of Alzheimer's disease
Y Li, T Liu, Q Zeng, M Cui - TrAC Trends in Analytical Chemistry, 2024 - Elsevier
Positron emission tomography (PET) is a non-invasive imaging technology that can reveal
molecular alterations in the brains of Alzheimer's disease (AD) patients with high sensitivity …
molecular alterations in the brains of Alzheimer's disease (AD) patients with high sensitivity …